Arvinas Secures IND Clearance for Oral LRRK2 Degrader ARV-102, Expanding Neurodegenerative Pipeline and Partnering with Michael J. Fox Foundation

Arvinas Press Release / MarketBeat / GLOBE NEWSWIRE USA

Overview

Arvinas announced FDA approval of its Investigational New Drug (IND) application for ARV-102, an oral PROTAC protein degrader designed for specific neurodegenerative diseases. This IND clearance marks a significant expansion of the company’s PROTAC platform beyond oncology. Furthermore, Arvinas has joined the Michael J. Fox Foundation’s LITE and PPMI programs to advance ARV-102 for Parkinson’s disease, committing to rigorous translational science and collaborative data generation.

In Depth

Key Findings

Arvinas, Inc. announced that its Investigational New Drug (IND) application for ARV-102, an orally available PROTAC protein degrader designed for neurodegenerative diseases, has been cleared by the U.S. FDA. This approval signifies a crucial milestone, as it expands the company’s targeted protein degradation platform beyond oncology into the challenging new therapeutic area of neurodegeneration.

Technical / Clinical Details

ARV-102 is a PROTAC (proteolysis-targeting chimera) specifically engineered to degrade Leucine-rich repeat kinase 2 (LRRK2) protein, a key genetic contributor to Parkinson’s disease. Preclinical studies have shown that ARV-102 can reduce LRRK2 expression by over 50%, a reduction believed to be therapeutically meaningful. With the IND clearance, Arvinas plans to initiate Phase 1b and Phase 2 clinical trials for ARV-102 in patients with Progressive Supranuclear Palsy (PSP) later this year. Additionally, to accelerate the development of LRRK2-targeting therapies for Parkinson’s disease, Arvinas has joined The Michael J. Fox Foundation’s LITE (LRRK2 Investigative Therapeutics Exchange) and PPMI (Parkinson’s Precision Medicine Initiative) programs, committing to rigorous translational science and collaborative data generation.

Background & Context

Neurodegenerative diseases, particularly Parkinson’s disease, represent an area of high unmet medical need due to a lack of effective disease-modifying therapies. PROTAC technology offers a novel therapeutic modality that functions by degrading disease-associated proteins, enabling an approach to previously ‘undruggable’ targets that conventional inhibitors could not address. As a pioneer in targeted protein degradation, Arvinas aims to apply this platform to diseases beyond cancer, striving to develop groundbreaking therapeutics. The collaboration with The Michael J. Fox Foundation underscores a commitment to patient community engagement and expedited clinical development.

Strategic Significance & Outlook

The initiation of clinical trials for ARV-102 and the strategic collaboration with The Michael J. Fox Foundation represent significant advancements in PROTAC-based drug development for Parkinson’s and other neurodegenerative disorders. The success of these programs holds the potential to revolutionize the treatment of neurodegenerative diseases, dramatically improving patients’ lives. Arvinas will continue to validate the value of this innovative technology through steady accumulation of clinical data.